About

The Origins

PAIR builds on the legacy of Horizon 2020 VIVALDI and CORONADX projects.

VIVALDI successfully developed and validated the VETPOD technology, a Point-of-Care (POC) instrument for detection of pathogens relevant for food safety — in particular, Salmonella detection.

CORONADX subsequently successfully validated VETPOD also for detection of SARS-CoV-2.

Validation data from both these projects will be used to develop PAIR’s technologies.

PAIR Overview

PAIR will develop 2 technologies: PANPOC and PANRISK.

Based on past pandemics, PAIR identified respiratory RNA target viruses to be detected: human and animal Influenza A (InfA, AIV and SIV), Influenza B and beta-CoV (SARS-CoV-2 variants and emerging beta-coronaviruses).

PANPOC is a Point-of-Care (POC) instrument for rapid detection of respiratory RNA viruses with pandemic potential in human, animal, and environmental samples. The pioneering technology will rest on a new fluorescence-based optical system for target virus detection and will include a touchscreen for fast and straightforward use.

PANRISK is a spatio-temporal epidemiologic model that processes field data from freely accessible online resources and proprietary partner results. Based on existing predictive methods, PANRISK will be able to monitor, evaluate and give an alarm in case of pandemic risk.

Objectives and Methodology

1.

PANPOC Phase: Detection and Diagnosis

PANPOC is Diagnostic Point-of-Care system for rapid and reliable detection of RNA respiratory viruses.

Steps:

  • PANPOC System development
  • PANPOC Analytical Validation
  • PANPOC Field performance on animal samples
  • PANPOC Clinical performance on human samples
2.

Between 2 Technologies: Database for PANRISK training

3.

PANRISK Phase: Prevention

PANRISK is a prognostic epidemiologic model to assess the risk of pandemics and help outbreak response and prevention.

Steps:

  • PANRISK Pathogen spillover model definition
  • PANRISK Zoonotic diseases epidemiological model
  • PANRISK Platform to assess the risk of pandemics
4.

Implementation at End-Users

PANPOC and PANRISK are implemented at veterinary and clinical end-users.

Guidelines will be delivered for:

  • PANPOC implementation in Primary and Secondary Care
  • PANRISK implementation at Veterinary and Health Authorities
  • Social aspects related to PANPOC and PANRISK implementation

Impacts

Science and technology

PAIR aims at a high Technological Readiness Level. This involves a very elevated degree of maturity of its technologies at the end of the project. A public database including the PANPOC test results and sequencing data will also be prepared, gathering a critical mass of biological material, laboratory and field data, know-how and innovative technologies. Also, the project aims to favour a long-term network of researchers in EU and US.

Society

Three years after the project’s end, both PANPOC and PANRISK systems will be commonly used for short time detection (15 minutes) and decision-making in terms of potential cross-border pandemics.
Not only will this involve a social impact by enhancing citizens’ trust, engagement and awareness about the importance of testing, caring and prevention, but also this will represent support for inclusivity by making a low-cost, effective testing device accessible even to disadvantaged groups (i.e. migrants, asylum seekers, etc.), especially within cross-border communities.

Policy

PAIR will improve pandemic preparedness within the EU, both at the national and transnational levels. Indeed, new Guidelines will be provided, with the aim to make radical improvement in Point-of Care (POC) diagnostic and epidemiological modelling in a European One Health genomic-informed approach. These new Guidelines will be ready for EU-wide implementation of both PANPOC and PANRISK technologies.

Industry

PAIR will provide primary care providers and health authorities with a novel, cost-effective solution to ensure fast diagnosis of potentially cross-border pandemic viruses. Commercial PANPOC and PANRISK tools will be available for end-users. The PANPOC system will be submitted for approval at World Organization for Animal Health (WOAH) for Avian Influenza Virus animal diagnostics and at EUDAMED for clinical use as a POC tool in clinical diagnostics.
In particular, PANPOC will be marketed in Turkey, the Middle East and subsequently worldwide in the global market.

Consortium